Wegovy treatment plans are personalised, focusing on metabolic health, quality of life, and prevention of weightrelated complications
With a molecular weight of approximately 4731 g/mol and a molecular formula of C221H342N46O68 (though some sources note C223H343F3N46O70 due to trifluoroacetate salt variations), Retatrutides structure supports its role as a triple agonist targeting glucagon (GCGR), glucose-dependent insulinotropic polypeptide (GIPR), and glucagon-like peptide-1 (GLP-1R) receptors
NICE guidance provides clear recommendations for GLP-1 use, which focus exclusively on glycaemic control in type 2 diabetes (NG28) and weight management in obesity (TA875 for semaglutide, TA664 for liraglutide)
Dehydration can worsen fatigue, dizziness, constipation, and weakness
CKD benefits were similar, with the FLOW trial (3,500 patients with T2D and chronic kidney disease), Semaglutide (1 mg weekly) reduced the risk of kidney failure events and death from kidney- or cardiovascular-related causes by 24% (HR 0.76
Alternatives to Peptide and GLP-1 Therapies Lifestyle Approaches: Nutrition, exercise, and behavioral therapies remain cornerstone solutions
